Home > Boards > US Listed > Medical - Drugs > Relmada Therapeutics Inc. (RLMD)

NEWS -- Relmada Therapeutics to Present at the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paulness Member Profile
 
Followed By 75
Posts 10,605
Boards Moderated 0
Alias Born 11/02/03
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/5/2021 4:09:28 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/31/2021 5:02:19 PM
Relmada Therapeutics EPS misses by $0.25 Seeking Alpha - 3/23/2021 4:31:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2021 5:17:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2021 5:14:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2021 5:52:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2021 5:51:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/10/2021 6:19:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/2/2021 4:08:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 5:07:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 4:59:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2021 4:55:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/17/2021 6:38:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:19:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:19:24 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:52:26 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:22:22 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:16:38 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 9:39:36 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2021 8:06:59 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/4/2021 5:42:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/4/2021 5:40:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/3/2021 6:35:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2021 5:06:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/2/2021 3:15:45 PM
Paulness   Tuesday, 06/09/20 09:34:54 AM
Re: None
Post # of 500 
NEWS -- Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

NEW YORK, June 9, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held June 9-11, 2020.

Fireside Chat Details:
  • Date: Thursday, June 11, 2020
  • Time: 3:00 PM EDT
  • Webcast: A live webcast of the fireside chat will be available by visiting the "Investors" section of the company's website: http://www.relmada.com. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.
About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://tim@lifesciadvisors.com

For Media Inquiries:
FischTank PR
mailto://relmada@fischtankpr.com

View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conference-301072754.html

SOURCE Relmada Therapeutics, Inc.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences